Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02501265 · ClinicalTrials.gov registry record · Phase 2
Adaptive Pharmacotherapy for Smoking Cessation
A Phase 2 study of Nicotine Dependence, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 188
- Enrollment target
- 1
- Study location
NCT02501265: Completed Phase 2 study of Nicotine Dependence, sponsored by Duke University.
NCT02501265 is a Phase 2 study of Nicotine Dependence that has completed, run by Duke University. The registered enrollment target is 188 participants, roughly in line with the 184-participant average among 67 other Nicotine Dependence trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02501265, a Phase 2 study of Nicotine Dependence, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 188 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess an "adaptive" approach to smoking cessation pharmacotherapy. The protocol is designed to compare adaptive vs. standard approaches to two common smoking cessation pharmacotherapies - Varenicline (commonly known as Chantix) and the Nicotine Patch. The investigators hypothesize that participants allocated to adaptive therapy will show significantly higher biochemically confirmed 30-day continuous abstinence at 12 weeks post-Target Quit Day (TQD).
Primary Outcome
Number of participants who self report complete smoking abstinence over the last 30 days and are also verified to be abstinent by carbon monoxide (CO) expired breath testing with CO \< 7 parts per million.
Conditions Studied
Interventions
- BEHAVIORAL Varenicline Standard Protocol
- BEHAVIORAL Nicotine Patch Standard Protocol
- DRUG Varenicline Adaptive Protocol
- DRUG Nicotine Adaptive Protocol
Study Locations (1)
North Carolina
- Duke Center for Smoking Cessation - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2017-06-06 |
| Est. Completion | 2021-05-12 |
| Phase | Phase 2 |
What the finished NCT02501265 record still lists
NCT02501265 is an interventional study that assigns participants to a tested intervention. The registered 188 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 184-participant average among 67 other Nicotine Dependence trials with a reported enrollment target.
The record links to 1 condition, with Nicotine Dependence appearing as the primary indexed condition, and to 4 interventions - of which Varenicline Standard Protocol is the first listed.
NCT02501265 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT02501265 about?
NCT02501265 is a clinical study titled "Adaptive Pharmacotherapy for Smoking Cessation". The purpose of this study is to assess an "adaptive" approach to smoking cessation pharmacotherapy. The protocol is designed to compare adaptive vs. standard approaches to two common smoking cessation pharmacotherapies - Varenicline (commonly known as Chantix) and the Nicotine Patch. The investigato...
What is the current status of trial NCT02501265?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 188 participants. The study started on 2017-06-06. Estimated completion is 2021-05-12.
What conditions does trial NCT02501265 study?
This clinical trial studies the following conditions: Nicotine Dependence.
What interventions are being tested in trial NCT02501265?
The interventions under investigation include: Varenicline Standard Protocol (BEHAVIORAL), Nicotine Patch Standard Protocol (BEHAVIORAL), Varenicline Adaptive Protocol (DRUG), Nicotine Adaptive Protocol (DRUG).
Who is sponsoring clinical trial NCT02501265?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02501265 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nicotine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02501265's enrollment target sits among peer trials
188 19th of 67 higher than 49 of 67 other Nicotine Dependence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Nicotine Dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Trial of Varenicline for E-cigarette Cessation
RECRUITING · Phase 2
-
Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity
COMPLETED · Phase 2
-
N-acetylcysteine for Tobacco Use Disorder
COMPLETED · Phase 2
-
Targeted Interventions for Weight-Concerned Smokers
COMPLETED · Phase 2
-
E-cigarette Nicotine Study
COMPLETED · Phase 2
-
Treatment of Smoking Among Individuals With PTSD
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422198 · 188 participants · Phase 3
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
- NCT04469790 · 188 participants · NA
Effects of Multi-day Interruptions in Sitting on Type 2 Diabetes-relevant Outcomes in Children
- NCT04671667 · 188 participants · Phase 2
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- NCT04853251 · 188 participants · Phase 4
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI